Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapyMehregan Babamohamadi, Jamshid Hadjati, Zhila Izadi et al.|Cell Death and Disease|2024Cited by 83
Recent findings on the role of wild-type and mutant p53 in cancer development and therapyMehregan Babamohamadi, Goran Othman, Burhan Ahmed Salih et al.|Frontiers in Molecular Biosciences|2022Cited by 31
Recent advances in targeting LRRK2 for Parkinson’s disease treatmentMahsa Karami, Zhila Izadi, Pantea Majma Sanaye et al.|Journal of Translational Medicine|2025Cited by 14
Types of RNA therapeuticsPouya Goleij, Hossein Motedayyen, Mehregan Babamohamadi et al.|Progress in molecular biology and translational science|2024Cited by 14
Phytostilbenes in lymphoma: Focuses on the mechanistic and clinical prospects of resveratrol, pterostilbene, piceatannol, and pinosylvinPouya Goleij, Haroon Khan, Mehregan Babamohamadi et al.|Leukemia Research|2024Cited by 14